贝达药业：公司第四代EGFR抑制剂BPI-361175因项目价值不明显，已暂缓开发

Group 1 - The company has paused the development of its fourth-generation EGFR inhibitor BPI-361175 due to its unclear project value [2] - Currently, the company is focusing on two clinical research projects in the lung cancer treatment field: MCLA-129 and CFT8919 [2] - The company aims to concentrate resources to expedite the development progress of new drug projects [2]